首页> 外文期刊>European journal of pharmaceutical sciences >Co-spray dried resveratrol and budesonide inhalation formulation for reducing inflammation and oxidative stress in rat alveolar macrophages
【24h】

Co-spray dried resveratrol and budesonide inhalation formulation for reducing inflammation and oxidative stress in rat alveolar macrophages

机译:共同喷雾干燥的白藜芦醇和布地奈德吸入制剂可减轻大鼠肺泡巨噬细胞的炎症和氧化应激

获取原文
获取原文并翻译 | 示例
           

摘要

Oxidative stress is instrumental in the pathogenesis and progression of chronic obstructive pulmonary disease (COPD). Novel therapeutic strategies that target macrophages, based on the use of antioxidant compounds, could be explored to improve corticosteroid responses in COPD patients. In this study, inhalable microparticles containing budesonide (BD) and resveratrol (RES) were prepared and characterized. This approach was undertaken to develop a multi-drug inhalable formulation with anti-oxidant and anti-inflammatory activities for treatment of chronic lung diseases. The inhalable microparticles containing different ratios of BD and RES were prepared by spray drying. The physico-chemical properties of the formulations were characterized in terms of surface morphology, particle size, physical and thermal stability. Additionally, in vitro aerosol performances of these formulations were evaluated with the multi-stage liquid impinger (MSLI) at 60 and 90 l/min, respectively. The cytotoxicity effect of the formulations was evaluated using rat alveolar macrophages. The biological responses of alveolar macrophages in terms of cytokine expressions, nitric oxide (NO) production and free radical scavenging activities were also tested. The co-spray dried (Co-SD) microparticles of all formulations exhibited morphologies appropriate for inhalation administration. Analysis of the deposition profiles showed an increase in aerosol performance proportional to BD concentration. Cell viability assay demonstrated that alveolar macrophages could tolerate a wide range of RES and BD concentrations. In addition, RES and BD were able to decrease the levels of tumour necrosis factor alpha (TNF-alpha) and interleukin-6 (IL-6) in lipopolysaccharide (LPS) induced alveolar macrophages.
机译:氧化应激在慢性阻塞性肺疾病(COPD)的发病机理和进展中起重要作用。可以探索基于抗氧化剂化合物的靶向巨噬细胞的新型治疗策略,以改善COPD患者的皮质类固醇反应。在这项研究中,制备并表征了包含布地奈德(BD)和白藜芦醇(RES)的可吸入微粒。采取这种方法来开发具有抗氧化和抗炎活性的多药可吸入制剂,用于治疗慢性肺部疾病。通过喷雾干燥制备含有不同比例的BD和RES的可吸入微粒。根据表面形态,粒度,物理和热稳定性来表征制剂的物理化学性质。另外,这些制剂的体外气雾剂性能分别通过多级液体冲击器(MSLI)以60和90 l / min的速度进行了评估。使用大鼠肺泡巨噬细胞评估制剂的细胞毒性作用。还测试了肺泡巨噬细胞在细胞因子表达,一氧化氮(NO)产生和自由基清除活性方面的生物学反应。所有配方的共同喷雾干燥(Co-SD)微粒均表现出适合吸入给药的形态。沉积曲线分析表明,气溶胶性能与BD浓度成正比。细胞活力测定表明,肺泡巨噬细胞可以耐受广泛的RES和BD浓度。此外,RES和BD能够降低脂多糖(LPS)诱导的肺泡巨噬细胞中肿瘤坏死因子α(TNF-alpha)和白介素6(IL-6)的水平。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号